AstraZeneca Licences Sino Biopharmaceutical’s TQC3721 Respiratory Drug in Potential $1.9bn Deal

The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China, expanding the company’s respiratory pipeline with an investigational PDE3/4 inhibitor targeting chronic respiratory diseases including chronic obstructive pulmonary disease (COPD). AstraZeneca and Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have entered into an exclusive licensing agreement for TQC3721, an inhaled phosphodiesterase 3/4 (PDE3/4) inhibitor currently in clinical development for respiratory diseases.

Under the agreement, AstraZeneca will gain rights to develop, manufacture and commercialise TQC3721 outside China, while also securing exclusive global rights to certain future development programmes.

Sino Biopharmaceutical will receive an upfront payment of $200 million from AstraZeneca, with additional development, regulatory and commercial milestones potentially increasing the total value of the collaboration to $1.9 billion.

The deal also includes tiered royalties on annual net sales, which could reach double-digit percentages for TQC3721 products.

AstraZeneca Expands Respiratory Pipeline With PDE3/4 Inhibitor

TQC3721 is an inhaled PDE3/4 inhibitor designed to deliver both bronchodilator and anti-inflammatory effects by targeting two pathways involved in respiratory disease.

Sino Biopharmaceutical is developing the therapy for chronic respiratory conditions, including chronic obstructive pulmonary disease (COPD), where persistent airway inflammation and reduced lung function remain significant treatment challenges.

The company believes dual inhibition of PDE3 and PDE4 could provide complementary benefits by improving lung function, reducing exacerbations and addressing broader disease burden compared with therapies targeting individual pathways.

The programme is being developed in two formulations:

• Nebulised TQC3721, currently being evaluated in a Phase III clinical trial in China.

• Dry powder inhaler formulation, currently being assessed in a Phase II study.
  

Phase IIb COPD Data Support Further Development

Early clinical data have strengthened interest in TQC3721 as a potential next-generation respiratory therapy.

In a Phase IIb study evaluating the nebulised formulation in patients with COPD, Sino Biopharmaceutical reported that TQC3721 demonstrated a potential best-in-class profile.

The positive findings supported progression into late-stage development, with the Phase III trial designed to further evaluate the therapy’s safety and efficacy in COPD patients.

If successful, TQC3721 could provide an additional treatment option in a respiratory market where companies continue to seek therapies capable of improving symptom control, reducing exacerbations and supporting long-term disease management.

Strategic Importance for AstraZeneca’s Respiratory Portfolio

The collaboration reinforces AstraZeneca’s continued focus on respiratory medicine, an area where the company has established a strong global presence through therapies for asthma and COPD.

By gaining access to TQC3721, AstraZeneca adds an investigational inhaled therapy with a differentiated mechanism of action to its pipeline.

The agreement combines Sino Biopharmaceutical’s discovery capabilities and clinical development progress in China with AstraZeneca’s global expertise in respiratory medicine and commercialisation infrastructure.

Sino Biopharmaceutical said the partnership will help accelerate the global development of TQC3721 and maximise its potential clinical and commercial value.

Growing Momentum Behind China Pharma Partnerships

The AstraZeneca-Sino Biopharmaceutical agreement reflects the growing role of Chinese biotechnology and pharmaceutical companies in global licensing activity.

For Sino Biopharmaceutical, the deal represents its second major out-licensing transaction with a multinational pharmaceutical company in 2026.

Earlier this year, the company entered into a separate collaboration with Sanofi involving the experimental oral JAK/ROCK inhibitor rovadicitinib.

AstraZeneca has also continued to expand its presence in China through strategic partnerships, including collaborations focused on innovative drug discovery platforms and emerging therapeutic areas.

Why the TQC3721 Deal Matters

The agreement highlights continued investment in next-generation respiratory medicines as pharmaceutical companies look beyond established COPD treatments.

For AstraZeneca, TQC3721 provides access to a late-stage respiratory asset with potential applications in a large and growing patient population.

For Sino Biopharmaceutical, the partnership provides global development expertise and commercial reach needed to advance its respiratory innovation beyond China.

A successful clinical programme could position TQC3721 as a potential differentiated treatment option for COPD and other chronic respiratory diseases.

Summary

AstraZeneca has signed an exclusive licensing agreement with Sino Biopharmaceutical subsidiary CTTQ for TQC3721, an inhaled PDE3/4 inhibitor being developed for chronic respiratory diseases including COPD.

The deal includes a $200 million upfront payment and could generate up to $1.9 billion in milestone payments, alongside tiered royalties.

Currently in Phase III development in China, TQC3721 represents AstraZeneca’s latest move to strengthen its respiratory pipeline through strategic partnerships and emerging global innovation.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com